company background image
MDGL

Madrigal Pharmaceuticals NasdaqGS:MDGL Stock Report

Last Price

US$66.45

Market Cap

US$1.1b

7D

14.5%

1Y

-50.4%

Updated

16 May, 2022

Data

Company Financials +
MDGL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MDGL Stock Overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

Madrigal Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Madrigal Pharmaceuticals
Historical stock prices
Current Share PriceUS$66.45
52 Week HighUS$137.78
52 Week LowUS$52.33
Beta1.27
1 Month Change-16.38%
3 Month Change-26.09%
1 Year Change-50.41%
3 Year Change-33.40%
5 Year Change305.68%
Change since IPO554.67%

Recent News & Updates

May 11
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Today we will run through one way of estimating the intrinsic value of Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL...

Apr 19

Madrigal: NASH Data In Q4 Is The Key

MDGL announced NAFLD data in January. The 2018 NASH data has some predictive value for the phase 3 NASH trial. This trial will produce data in Q4.

Feb 24
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

MDGLUS BiotechsUS Market
7D14.5%4.8%0.7%
1Y-50.4%-22.0%-10.8%

Return vs Industry: MDGL underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: MDGL underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is MDGL's price volatile compared to industry and market?
MDGL volatility
MDGL Average Weekly Movement8.9%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: MDGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MDGL's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a71Paul Friedmanhttps://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom.

Madrigal Pharmaceuticals Fundamentals Summary

How do Madrigal Pharmaceuticals's earnings and revenue compare to its market cap?
MDGL fundamental statistics
Market CapUS$1.14b
Earnings (TTM)-US$246.82m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDGL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$246.82m
Earnings-US$246.82m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-14.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MDGL perform over the long term?

See historical performance and comparison

Valuation

Is Madrigal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MDGL ($66.45) is trading below our estimate of fair value ($1323.61)

Significantly Below Fair Value: MDGL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MDGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MDGL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDGL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDGL is overvalued based on its PB Ratio (7.8x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Madrigal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


69.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDGL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDGL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDGL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDGL's revenue (76.5% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: MDGL's revenue (76.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MDGL is forecast to be unprofitable in 3 years.


Past Performance

How has Madrigal Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-48.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDGL is currently unprofitable.

Growing Profit Margin: MDGL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDGL is unprofitable, and losses have increased over the past 5 years at a rate of 48% per year.

Accelerating Growth: Unable to compare MDGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MDGL has a negative Return on Equity (-169.35%), as it is currently unprofitable.


Financial Health

How is Madrigal Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDGL's short term assets ($221.2M) exceed its short term liabilities ($76.6M).

Long Term Liabilities: MDGL's short term assets ($221.2M) exceed its long term liabilities ($283.0K).


Debt to Equity History and Analysis

Debt Level: MDGL is debt free.

Reducing Debt: MDGL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDGL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.4% each year


Dividend

What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDGL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDGL has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Paul Friedman (78 yo)

5.83yrs

Tenure

US$5,318,389

Compensation

Dr. Paul A. Friedman, M.D., has been Independent Chairman of the Board at Prelude Therapeutics Incorporated and has been its Independent Director since July 2016. He has been Chairman and Chief Executive O...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD5.32M) is above average for companies of similar size in the US market ($USD3.88M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MDGL's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: MDGL's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Company Information

Madrigal Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Madrigal Pharmaceuticals, Inc.
  • Ticker: MDGL
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.137b
  • Shares outstanding: 17.10m
  • Website: https://www.madrigalpharma.com

Number of Employees


Location

  • Madrigal Pharmaceuticals, Inc.
  • Four Tower Bridge
  • Suite 200
  • West Conshohocken
  • Pennsylvania
  • 19428
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.